アブストラクト
Japanese
| Title | C型肝炎 治療の変遷 |
|---|---|
| Subtitle | 特集 肝炎 : 過去・現在・未来 |
| Authors | 四柳宏 |
| Authors (kana) | |
| Organization | 東京大学医科学研究所 先端医療研究センター・感染症分野 附属病院・感染免疫内科 |
| Journal | 臨床とウイルス |
| Volume | 48 |
| Number | 2 |
| Page | 146-149 |
| Year/Month | 2020 / 7 |
| Article | 報告 |
| Publisher | 日本臨床ウイルス学会 |
| Abstract | 〔論文要旨〕C型肝炎ウイルス(hepatitis C virus, 以下HCV)の治療はインターフェロン単独療法→ペグインターフェロン単独療法→ペグインターフェロン・リバビリン併用療法→ペグインターフェロン・リバビリン・DAA(direct-acting antivirals)併用療法→DAA併用療法と変遷してきた. 現在は前治療不成功例, 非代償肝硬変例などにも治療が広がり, ほとんどの患者でウイルス排除が可能になった. 今後はウイルス排除後の合併症が問題となってくるものと思われる. |
| Practice | 臨床医学：内科系 |
| Keywords | インターフェロン, 遺伝子型, ペグインターフェロン, DAA, IFNフリー療法, interferon, HCV genotype, pegylated-interferon, direct-acting antivirals, interferon-free therapy |
English
| Title | Changes in hepatitis C treatment |
|---|---|
| Subtitle | |
| Authors | Hiroshi YOTSUYANAGI |
| Authors (kana) | |
| Organization | The University of Tokyo, The Institute of Medical Science, Research Hospital Division of Infectious Diseases and Applied Immunology |
| Journal | Clinical Virology |
| Volume | 48 |
| Number | 2 |
| Page | 146-149 |
| Year/Month | 2020 / 7 |
| Article | Report |
| Publisher | Japanese Society of Clinical Virology |
| Abstract | HCV treatment started from interferon monotherapy, followed by pegylated-interferon monotherapy, pegylated-interferon plus ribavirin combination therapy, pegylated-interferon and ribavirin plus direct-acting antivirals (DAA) combination therapy, and DAA combination therapy. At present, HCV patients with pretreatment failure or decompensated cirrhosis can be treated. The virus can be eradicated by antivirals in almost all patients. Complications after the clearance of HCV are future problems. |
| Practice | Clinical internal medicine |
| Keywords | DAA, interferon, HCV genotype, pegylated-interferon, direct-acting antivirals, interferon-free therapy |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Hoofnagle JH, Mullen KD, Jones DB, et al.:Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315:1575-1578.
- 2) Poynard T, Marcellin P, Lee SS, et al.:Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group(IHIT). Lancet 1998;352:1426-1432.
- 3) Watanabe S, Enomoto N, Koike K, et al.:Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2010;40:135-144.
- 4) Tanaka Y, Nishida N, Sugiyama M, et al.:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
- 5) Lohmann V, Korner F, Koch J, et al.:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
残りの5件を表示する
- 6) Wakita T, Pietschmann T, Kato T, et al.:Produc-tion of infectious hepatitis C Virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
- 7) Kosaka K, Imamura M, Hayes CN, et al.:Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat 2015;22:158-165.
- 8) Reddy KR, Bourliere M, Sulkowski M, et al.:Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis:an integrated safety and efficacy analy-sis. Hepatology 2015;62:79-86.
- 9) Izumi N, Takehara T, Chayama K, et al.:Sofosbu-vir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 2018;12:356-367.
- 10) Takehara T, Sakamoto N, Nishiguchi S, et al.:Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis:an open-label phase 3 trial. J Gastroenterol 2019;54:87-95.
